These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 19225402)

  • 1. Nonalcoholic fatty liver disease among HIV-infected persons.
    Crum-Cianflone N; Dilay A; Collins G; Asher D; Campin R; Medina S; Goodman Z; Parker R; Lifson A; Capozza T; Bavaro M; Hale B; Hames C
    J Acquir Immune Defic Syndr; 2009 Apr; 50(5):464-73. PubMed ID: 19225402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors.
    Guaraldi G; Squillace N; Stentarelli C; Orlando G; D'Amico R; Ligabue G; Fiocchi F; Zona S; Loria P; Esposito R; Palella F
    Clin Infect Dis; 2008 Jul; 47(2):250-7. PubMed ID: 18532884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease.
    Guaraldi G; Lonardo A; Ballestri S; Zona S; Stentarelli C; Orlando G; Carli F; Carulli L; Roverato A; Loria P
    Arch Med Res; 2011 Nov; 42(8):690-7. PubMed ID: 22227046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infection.
    Nishijima T; Gatanaga H; Shimbo T; Komatsu H; Nozaki Y; Nagata N; Kikuchi Y; Yanase M; Oka S
    PLoS One; 2014; 9(1):e87596. PubMed ID: 24498148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection.
    Li Vecchi V; Soresi M; Giannitrapani L; Di Carlo P; Mazzola G; Colletti P; Terranova A; Vizzini G; Montalto G
    Int J Infect Dis; 2012 May; 16(5):e397-402. PubMed ID: 22425495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV.
    Lake JE; Taron J; Ribaudo HJ; Leon-Cruz J; Utay NS; Swaminathan S; Fitch KV; Kileel EM; Paradis K; Fulda ES; Ho KS; Luetkemeyer AF; Johnston CD; Zanni MV; Douglas PS; Grinspoon SK; Lu MT; Fichtenbaum CJ;
    AIDS; 2023 Nov; 37(14):2149-2159. PubMed ID: 37503623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse.
    Sterling RK; Smith PG; Brunt EM
    J Clin Gastroenterol; 2013 Feb; 47(2):182-7. PubMed ID: 23059409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVIH).
    Nordmann S; Vilotitch A; Roux P; Esterle L; Spire B; Marcellin F; Salmon-Ceron D; Dabis F; Chas J; Rey D; Wittkop L; Sogni P; Carrieri P;
    J Viral Hepat; 2018 Feb; 25(2):171-179. PubMed ID: 28984055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3.
    Borghi V; Puoti M; Mussini C; Bellelli S; Angeletti C; Sabbatini F; Prati F; Cossarizza A; Esposito R
    Antivir Ther; 2008; 13(8):1057-65. PubMed ID: 19195331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    Pembroke T; Deschenes M; Lebouché B; Benmassaoud A; Sewitch M; Ghali P; Wong P; Halme A; Vuille-Lessard E; Pexos C; Klein MB; Sebastiani G
    J Hepatol; 2017 Oct; 67(4):801-808. PubMed ID: 28527666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus.
    Woreta TA; Sutcliffe CG; Mehta SH; Brown TT; Higgins Y; Thomas DL; Torbenson MS; Moore RD; Sulkowski MS
    Gastroenterology; 2011 Mar; 140(3):809-17. PubMed ID: 21134375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.
    Vuille-Lessard É; Lebouché B; Lennox L; Routy JP; Costiniuk CT; Pexos C; Giannakis A; Szabo J; Klein MB; Sebastiani G
    AIDS; 2016 Nov; 30(17):2635-2643. PubMed ID: 27603289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence and clinical correlates of nonalcoholic fatty liver disease (NAFLD) in African Americans: the multiethnic study of atherosclerosis (MESA).
    Foster T; Anania FA; Li D; Katz R; Budoff M
    Dig Dis Sci; 2013 Aug; 58(8):2392-8. PubMed ID: 23546700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease.
    Kwak MS; Kim D; Chung GE; Kang SJ; Park MJ; Kim YJ; Yoon JH; Lee HS
    Clin Mol Hepatol; 2012 Dec; 18(4):383-90. PubMed ID: 23323254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral contraceptive pill use is associated with reduced odds of nonalcoholic fatty liver disease in menstruating women: results from NHANES III.
    Liu SH; Lazo M; Koteish A; Kao WH; Shih MH; Bonekamp S; Hernaez R; Clark JM
    J Gastroenterol; 2013 Oct; 48(10):1151-9. PubMed ID: 23188092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus.
    Marks KM; Petrovic LM; Talal AH; Murray MP; Gulick RM; Glesby MJ
    J Infect Dis; 2005 Dec; 192(11):1943-9. PubMed ID: 16267765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons.
    Crum-Cianflone N; Collins G; Medina S; Asher D; Campin R; Bavaro M; Hale B; Hames C
    Clin Gastroenterol Hepatol; 2010 Feb; 8(2):183-91. PubMed ID: 19800985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.
    Martinez V; Ta TD; Mokhtari Z; Guiguet M; Miailhes P; Valantin MA; Charlotte F; Bertheau P; Molina JM; Katlama C; Caumes E
    BMC Res Notes; 2012 Jul; 5():180. PubMed ID: 22490728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease, liver fibrosis, and cardiometabolic risk factors in adolescence: a cross-sectional study of 1874 general population adolescents.
    Lawlor DA; Callaway M; Macdonald-Wallis C; Anderson E; Fraser A; Howe LD; Day C; Sattar N
    J Clin Endocrinol Metab; 2014 Mar; 99(3):E410-7. PubMed ID: 24471572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey.
    Sirota JC; McFann K; Targher G; Johnson RJ; Chonchol M; Jalal DI
    Metabolism; 2013 Mar; 62(3):392-9. PubMed ID: 23036645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.